Robotrak, since its inception in 2017, has been synonymous with innovation in ophthalmology, catering to a diverse age range with our groundbreaking solutions. Positioned at the nexus of technology and healthcare, our company has made significant strides in the industry and set new benchmarks in eye disease screening.

Operating from our headquarters and R&D centers in Nanjing, China, and extending our capabilities through our global subsidiaries, we have created a robust network that integrates research, production, marketing, and service seamlessly. This unique ecosystem enables us to deliver unparalleled eye health lifecycle management solutions across the globe.

Our portfolio showcases our commitment to innovation, with the world's first commercialization of AO-SLO technology and the development of advanced intelligent navigated laser therapy systems. Our offerings extend to multi-mode ophthalmic imaging systems for animals and auto axial length/refractometer, signifying our versatility and focus on comprehensive eye care.

Moreover, our foray into functional soft contact lenses, including options for myopia control in teenagers and cosmetic lenses, underlines our dedication to addressing a broad spectrum of ophthalmic needs. Our efforts in AI-assisted diagnosis and treatment in ophthalmology further exemplify our commitment to leveraging technology for better health outcomes.

At Robotrak, we are driven by the vision that everyone deserves a clearer world, a principle that guides our every innovation and decision. Inspired by the transformative power of science and our foundational ethos, we are dedicated to delivering medical devices that change lives and enhance families' well-being worldwide.